Benzalkonium chloride
Benzalkonium chloride is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
73 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glaucoma | D005901 | EFO_0000516 | H40 | — | 1 | 2 | 8 | 2 | 13 |
| Ocular hypertension | D009798 | EFO_1001069 | H40.0 | — | 1 | 1 | 4 | 1 | 7 |
| Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | — | 1 | 1 | 3 | 1 | 6 |
| Healthy volunteers/patients | — | — | — | 1 | 1 | — | 1 | 2 | 5 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | 1 | 1 | 1 | 1 | 4 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | 2 | 2 | 4 |
| Respiratory tract infections | D012141 | — | J06.9 | — | — | — | 2 | 1 | 3 |
| Communicable diseases | D003141 | — | — | — | — | — | 1 | 2 | 3 |
| Eye diseases | D005128 | EFO_0003966 | H44 | 1 | — | — | 1 | — | 2 |
| Dry eye syndromes | D015352 | — | H04.12 | — | — | — | 2 | — | 2 |
Show 16 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anterior uveitis | D014606 | EFO_1000811 | — | — | — | 1 | — | 1 | 2 |
| Corneal ulcer | D003320 | — | H16.0 | — | 2 | 2 | — | — | 2 |
| Keratitis | D007634 | — | H16 | — | 2 | 2 | — | — | 2 |
| Ulcer | D014456 | MPATH_579 | — | — | 2 | 2 | — | — | 2 |
| Bacterial conjunctivitis | D003234 | EFO_1000829 | H10.0 | — | — | 1 | — | — | 1 |
| Conjunctivitis | D003231 | — | H10 | — | — | 1 | — | — | 1 |
| Corneal diseases | D003316 | — | H18.9 | — | — | 1 | — | — | 1 |
| Vaginitis | D014627 | EFO_0005757 | N76 | — | 1 | 1 | — | — | 1 |
| Fibrosis | D005355 | — | — | — | — | 1 | — | — | 1 |
| Idiopathic pulmonary fibrosis | D054990 | — | J84.112 | — | — | 1 | — | — | 1 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | — | 2 | — | — | 1 | 3 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 2 | — | — | — | 2 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 2 | — | — | — | 2 |
| Covid-19 | D000086382 | — | U07.1 | 1 | 1 | — | — | — | 2 |
| Cystinosis | D003554 | — | E72.04 | — | 1 | — | — | — | 1 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | 1 | — | — | — | 1 |
| Rhinitis | D012220 | EFO_0008521 | J31 | — | 1 | — | — | — | 1 |
| Myopia | D009216 | EFO_0003927 | H52.1 | — | 1 | — | — | — | 1 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | 1 | — | — | — | 1 |
| Hematopoietic stem cell transplantation | D018380 | — | — | — | 1 | — | — | — | 1 |
Show 3 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alcoholism | D000437 | EFO_0003829 | F10.1 | 1 | — | — | — | — | 1 |
| Alcohol-related disorders | D019973 | — | F10 | 1 | — | — | — | — | 1 |
| Presbyopia | D011305 | — | H52.4 | 1 | — | — | — | — | 1 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Aortic valve stenosis | D001024 | EFO_0000266 | — | — | — | — | — | 2 | 2 |
| Cataract | D002386 | EFO_0001059 | H26.9 | — | — | — | — | 1 | 1 |
| Macular edema | D008269 | — | — | — | — | — | — | 1 | 1 |
| Uveitis | D014605 | EFO_1001231 | H20.9 | — | — | — | — | 1 | 1 |
| Iritis | D007500 | EFO_1000997 | — | — | — | — | — | 1 | 1 |
| Iridocyclitis | D015863 | — | H20 | — | — | — | — | 1 | 1 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | — | 1 | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | — | 1 | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | — | — | 1 | 1 |
| Hyperparathyroidism | D006961 | EFO_0008506 | E21.3 | — | — | — | — | 1 | 1 |
Show 12 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Benzalkonium chloride |
| INN | benzalkonium chloride |
| Description | Benzalkonium chloride (BZK, BKC, BAK, BAC), also known as alkyldimethylbenzylammonium chloride (ADBAC) and by the trade name Zephiran, is a type of cationic surfactant. It is an organic salt classified as a quaternary ammonium compound. ADBACs have three main categories of use: as a biocide, a cationic surfactant, and a phase transfer agent. ADBACs are a mixture of alkylbenzyldimethylammonium chlorides, in which the alkyl group has various even-numbered alkyl chain lengths.
|
| Classification | Small molecule |
| Drug class | quaternary ammonium derivatives; quaternary ammonium derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1.[Cl-] |
Identifiers
| PDB | — |
| CAS-ID | 8001-54-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL502109 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | F5UM2KM3W7 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 14,073 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
487 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use